Oncoinvent publishes positive phase 1 data for Radspherin in ovarian cancer

Oncoinvent, a clinical-stage radiopharmaceutical company, has published 12-month Phase 1 study results for Radspherin® in platinum-sensitive recurrent ovarian cancer and peritoneal carcinomatosis in *Gynecologic Oncology*. The study's primary objectives were to assess safety and tolerability of the [224]Ra-labeled microparticles and determine the recommended dose. All dose levels were well tolerated, with no dose-limiting toxicity observed, and 7 MBq was selected as the recommended dose for the expansion phase.

Alongside the 12-month publication, Oncoinvent also released topline 24-month follow-up data from the Phase 1 study. The company is currently conducting a randomized controlled Phase 2 study to evaluate Radspherin's efficacy and safety in patients with peritoneal metastasis from ovarian cancer. This study aims to compare progression-free survival between Radspherin-treated patients and those receiving pre-operative chemotherapy and surgery alone.

Radspherin is an investigational radiopharmaceutical consisting of calcium carbonate microparticles containing radium-224, designed for local treatment of cancer spread to body cavities. Oncoinvent states early clinical efficacy data are highly encouraging, with no serious toxicity or safety concerns reported to date.